4 Biotechs Ready to Kill the Market in 2018 Post author:Sam Post published:December 28, 2017 Post category:BioPharma A look at a few biotechs which should outperform the market in 2018: Source: BioSpace You Might Also Like Prevail Therapeutics Grabs $75 Million to Advance Parkinson’s Disease Programs March 7, 2018 Why Bluebird Bio Investors Aren't Singing the Blues December 12, 2017 Why Bay Area's Exelixis Surged 22% in January February 1, 2017
